INTRODUCTION
Among the many proteins and metabolites secreted by adipocytes, adiponectin serves a unique role as a salutary, antidiabetic, insulin-sensitizing factor that has antiatherogenic and anti-inflammatory properties in the vasculature. Numerous epidemiological studies have shown that reduced adiponectin levels correlate with increased risk of cardiovascular disease in obese individuals and in patients with diabetes and hyperglycemia. 1, 2 These high-risk patients also have increased concentrations of circulating cytokines such as tumor necrosis factor (TNF). These cytokines exert detrimental effects on endothelial cell function 3 by increasing the production of reactive oxygen species (ROS) and triggering an inflammatory signaling cascade that results in increased cell-surface expression of cell adhesion molecules. These cell adhesion molecules enhance leukocyteendothelium interactions and incite some of the early changes that lead to atherosclerosis. 4 In most but not all clinical trials, [5] [6] [7] [8] [9] increased adiponectin levels have correlated with improved endothelial function. Adiponectin has been shown to ameliorate the progression of macrovascular disease in rodents; neointimal proliferation is attenuated in mechanically injured arteries of adiponectin knock-out (Adipoq -/-) mice, 10, 11 atherosclerotic lesion formation is decreased in apolipoprotein-Edeficient mice, 12, 13 and hypertension is ameliorated in obese mice. 14 Adiponectin specifically binds to collagens in the vascular intima and has been found to accumulate in the vascular wall of catheter-injured vessels, but not in unharmed control vessels. 15 Whether the vasculature-related effects mentioned above are mediated by the same receptors that transduce cellular signals from different forms of adiponectin is not known. In addition to its effects on the vasculature, adiponectin is known to be cardioprotective. Adipoq -/-mice undergo worse myocardial ischemia-reperfusion (MIR) injury than wild type control mice, injury that can be ameliorated by provision of adiponectin. 16, 17 Rather than focusing on the insulinsensitizing effects of adiponectin, this Review will explore the effects and underlying signaling mechanisms of adiponectin in the microvasculature and myocardium.
ADIPONECTIN STRUCTURE AND FUNCTION
Adiponectin (~30 kDa in size) is secreted from adipose tissue and circulates in the bloodstream at high levels, in the range of ~2-17 μg/ml. 1, 18 The dramatically high levels of adiponectin in the bloodstream, compared with other hormones and cytokines, are of great interest to many researchers. Adiponectin circulates in large, posttranslationally modified complexes that reduce the actual concentration of the individual molecules in plasma and are likely to influence the signaling potential of its various isoforms. Serum levels of adiponectin are approximately twofold higher in females than in males, which probably contributes to sex-related differences in some of its vascular protective effects.
Full-length adiponectin requires post-translational modifications for activity (e.g. hydroxylation and glycosylation) 19 and is secreted from adipocytes in three major size classes-trimers that are ~90 kDa in size (the basic unit), low molecular weight hexamers (~180 kDa) and high molecular weight isoforms (12-18-mers) that can be more than 400 kDa in size (Figure 1) . 20, 21 Differences in the functions of the various isoforms of adiponectin are currently being elucidated. Both low molecular weight and high molecular weight adiponectin induce apoptosis in nondifferentiated THP1 cells (a human acute monocytic leukemia cell line), reduce expression of macrophage scavenger receptor A messenger RNA, and activate AMP kinase. However, although the low molecular weight form reduces lipopolysaccharide-mediated interleukin-6 release and suppresses nuclear factor κB (NFκB) activation, high molecular weight adiponectin induces interleukin-6 secretion in human monocytes and THP1 cells and does not suppress lipopolysaccharide-induced interleukin-6 secretion. 22 These disparate results could reflect cell-type specificity and other experimental differences.
The C-terminal globular domain of adiponectin is a recombinant fragment of 137 amino acids generated in vitro; this fragment has potent pharmacological signaling activity, affects systemic glucose metabolism, and also has effects on the microvasculature and heart. [23] [24] [25] Whether this fragment is present in notable levels in the circulation, however, remains a point of debate. 18, 26 The globular and full-length oligomers reportedly differ in metabolic signaling effects; 18, 27 however, in endothelial cells, they exert comparable effects in suppressing increased ROS production induced by increased glucose levels. 28 Further work is needed to characterize the signaling effects of globular adiponectin, as well as those of the major ncpcardio_2007_280f1.eps Post-translational modification Figure 1 Structure of adiponectin. Full-length adiponectin requires post-translational modifications for activity (e.g. hydroxylation and glycosylation). Adiponectin molecules are secreted from adipocytes as trimers (~90 kDa; the basic unit), low molecular weight hexamers (~180 kDa) and high molecular weight isoforms (12-18-mers; >400 kDa). Abbreviations: aa, amino acids; C, carboxy terminal; HMW, high molecular weight; LMW, low molecular weight; N, amino terminal.
oligomeric forms of full-length adiponectin that occur in the mammalian circulation. Two structurally related transmembrane receptors for adiponectin have been identified-adiponectin receptor proteins 1 and 2 (ADIPOR1 and ADIPOR2). 27 ADIPOR1 and ADIPOR2 belong to a new family of membrane receptors that are predicted to contain seven transmembrane domains but are structurally and topologically distinct from G-protein-coupled receptors. Adiponectin binds to the C-terminal extracellular domain of ADIPOR1; the N-terminal cytoplasmic domain of the receptor interacts with the adaptor protein APPL 1 (adaptor protein containing pleckstrin homology domain, phosphotyrosine-binding domain and a leucine zipper motif 1). ADIPOR1 is abundantly expressed in skeletal muscle and has high affinity for globular adiponectin, whereas ADIPOR2 is predominantly expressed in the liver and has high affinity for full-length adiponectin. 27 These receptors are also found in endothelial cells 29 and cardiomyocytes; 30 they probably have a key signaling role in mediating the vascular and myocardial effects of adiponectin. Considerable evidence exists that adiponectin achieves its biologic function by activation of AMP kinase and PPARα (peroxisome proliferator-activated receptor α), although the precise pathways that lead to their activation remain largely unknown. In addition to these two receptors, T-cadherin is a putative cell-surface binding protein for fulllength and oligomeric adiponectin; T-cadherin is found in various cell types, such as those of the myocardium and vasculature. 31 
ADIPONECTIN AND THE MICROVASCULATURE
The microvasculature is the largest component of the cardiovascular system and contains the greatest amount of vascular endothelium. In addition to regulating systemic arterial blood pressure, the microvasculature is crucial for the homeostasis of organ nutrient supply and organ function throughout the body. The processes that underlie atherosclerosis of conduit vessels have been postulated to be closely tied to microvascular dysfunction; in large arteries, inflammation develops in the abundant plexi of microvessels in connection with their vasa vasorum. 32, 33 These microvascular networks are likely to contribute to lesion formation, as they provide an abundant surface area for leukocyte trafficking and serve as a portal for entry and exit of leukocytes from established atheroma in the conduit vessels. 34, 35 Many studies clearly implicate reduced adiponectin levels in macrovascular disease; however, to date, only a few reports have been published on the action of adiponectin on microvascular function.
Reduction of oxidative stress
Levels of circulating adiponectin are inversely correlated with plasma levels of oxidized LDL in patients with type 2 diabetes and coronary artery disease, which suggests that low adiponectin levels are associated with an increased oxidative state in the arterial wall. 36 Reduced adiponectin levels also correlate with increased measures of systemic oxidant stress. 37 Furthermore, the raised endothelial ROS production that is stimulated by multiple agonists, including oxidized LDL and high glucose levels, is suppressed in vitro by recombinant globular adiponectin in a dose-dependent manner. 28, 29 As endothelial ROS generation involves both mitochondrial ROS production and NADPH oxidases, 3, 38, 39 adiponectin probably acts on these molecules to reduce oxidative stress.
Anti-inflammatory actions
In metabolic diseases such as diabetes and obesity, inflammation of the systemic microcirculation is widely appreciated to underlie organ damage and other chronic complications. Consistent with the epidemiologic association of reduced adiponectin levels in patients who are obese and in those who have type 2 diabetes, in vitro studies have shown that adiponectin can reverse the deleterious endothelial effects of TNF and other cytokines, as well as high glucose levels, 1,2 which trigger an inflammatory signaling cascade, enhance leukocyte-endothelial interactions and, therefore, lead to some of the early processes of atherosclerosis ( Figure 2 ). The microvascular inflammation observed in Adipoq -/-mice 24 is thus consistent with the development of cardiovascular complications in individuals with diminished circulating levels of adiponectin, as shown in many epidemiological studies noted above. 1, 2 In theseAdipoq -/-mice, adiponectin replacement therapy, which used globular adiponectin, reversed the inflammatory phenotype of the microvascular endothelium and thus uncovered a potential therapeutic use of globular adiponectin, and possibly other synthetic forms of adiponectin in vivo.
Adiponectin binds to aortic endothelial cells and inhibits TNF-induced expression of cell adhesion molecules. 12, 40, 41 Modulation of vascular inflammation via downregulation of endothelial cell adhesion molecules was one of the first vascular protective actions of adiponectin to be described in vitro. 40 Indeed, we expanded on this seminal finding and demonstrated that in the microcirculation of Adipoq -/-mice a considerable increase exists in endothelial expression of the atherogenic cell adhesion molecules E-selectin and vascular cell adhesion molecule 1 (V-CAM 1). These molecules are associated with heightened leukocyte trafficking into mesenteric tissue. 24 Adiponectin also protects against endothelial monolayer hyperpermeability induced by angiotensin II or TNF; this effect has been observed for both globular and full-length adiponectin and is associated with amelioration of actin stress fibers, intercellular gap formation and β-tubulin disassembly. 42 Most of the anti-inflammatory actions of adiponectin studied in vitro have been linked to activation of endothelial nitric oxide synthase (eNOS) and increased bioavailability of nitric oxide (NO) at the vascular endothelium. Several groups have shown increased endothelial NO availability in response to adiponectin, 29, 43, 44 the mechanism of which involves adiponectin-stimulated binding of regulatory heat shock protein 90 (Hsp90) to eNOS. 45 Consistent with these in vitro data, adiponectin inhibition of leukocyte adhesion in TNF-inflamed microvascular networks in vivo is hindered by pharmacologic blockade of eNOS with N Ω -nitro-l-arginine methyl ester. 24 A major role for AMP kinase in the effects of adiponectin on glucose and fat metabolism has been amply demonstrated in liver, skeletal muscle and adipose cells. 1, 18, 48 AMP kinase also mediates at least some of the vascular effects of adiponectin in endothelial cells, especially those involving eNOS activation. 43, 46, 47 The enhancement of endothelial NO availability by adiponectin is linked to activation of AMP kinase, as well as signaling through phosphatidylinositol 3´-kinase. 43 Indeed, effects of adiponectin on angiogenesis were found to be dependent on adiponectinstimulated phosphorylation of both AMP kinase and Akt (protein kinase B). AMP kinase was found to act upstream of Akt, since disruption of AMP kinase activation inhibited adiponectininduced Akt phosphorylation. 47 Interestingly, inhibition of AMP kinase does not block globular adiponectin suppression of glucose-induced ROS generation, 28 which suggests that this action of globular adiponectin might be largely independent of AMP kinase in endothelial cells.
Pathways that involve protein kinase A (PKA, or cyclic AMP [cAMP]-dependent protein kinase) signaling have also been implicated in the effects of adiponectin in the endothelium. 28 induced by high glucose levels was also accompanied by increased cellular cAMP content and blocked by inhibition of PKA in endothelial cells. 28 These findings indicate that the cAMP-PKA pathway is a major signaling system that mediates the effects of adiponectin in endothelial cells to reverse the diverse cellular actions of TNF and high glucose levels. At the same time as suppressing inflammatory NFκB activation incited by either TNF or high glucose levels, globular adiponectin potently suppresses activation of the upstream enzyme IκB kinase (IKKβ). 50 cAMP signaling is implicated in this pathway; the adenylate cyclase activator forskolin mimics the action of globular adiponectin, whereas the adenylate cyclase inhibitor dideoxyadenosine, as well as the PKA inhibitor Rp-cAMP, block the inhibitory effect of globular adiponectin on TNF-induced IKKβ activity. 50 Interestingly, although adiponectin-induced AMP kinase and cAMP pathways have been shown to be comparably active in suppressing the TNFinduced increase in IKKβ, activation of AMP kinase is substantially more effective than cAMP signaling in suppressing IKKβ activity induced by increased glucose levels. 50 These findings imply that multiple pathways are involved in the suppression of endothelial inflammatory signaling by adiponectin.
The importance of suppression of endothelial ROS generation relative to eNOS stimulation by adiponectin in the balancing of NO availability remains unresolved. However, given that both AMP kinase-eNOS and PKA-ROS-suppression signal transduction pathways are implicated in adiponectin signaling in endothelial cells, potential crosstalk between these two pathways is of great importance and warrants further investigation. To date, the only documented crosstalk has been that upstream AMP kinase kinase LKB1 (serine threonine protein kinase II) can be phosphorylated by PKA. 52 
Angiogenesis
Interestingly, some studies have also implicated adiponectin in neoangiogenesis. Adiponectin has been shown to stimulate the differentiation of human umbilical vein endothelial cells into capillary-like structures in vitro via an AMP kinase-eNOS-mediated mechanism. 47 Furthermore, impaired angiogenesis in hind limbs of Adipoq -/-mice subjected to ischemic stress can be ameliorated by replenishment of adiponectin, in an AMP kinase-dependent manner. 53 In contrast to these results, adiponectin has also been reported to function as a negative regulator of angiogenesis; it potently inhibits endothelial cell proliferation and migration, and remarkably prevents new blood vessel growth. 54 Globular adiponectin has been shown to reduce endothelial cell proliferation and activation of p42/ p44 mitogen-activated protein kinase in vitro. 29 Migration of coronary artery endothelial cells, which is induced by vascular endothelial growth factor, is also suppressed by globular adiponectin. This feature is associated with a reduction in ROS generation, diminished activation of mitogenactivated protein kinase and the RhoGTPase RhoA, and reduced formation of actin stress fibers and focal cellular adhesions-all of which are mediated by cAMP-PKA signaling. 51 In another vascular model, adiponectin has been shown to inhibit laser-induced choroidal neovascularization in vivo. 55 Discrepancies between these results could be explained by different experimental conditions. However, the effect of endogenous adiponectin levels on reparative or maladaptive angiogenesis in cardiovascular disease remains unclear and deserves further investigation.
Localized generation of adiponectin
At the organ level, an emerging concept in the literature is that the microvascular endothelium modulates local levels of adiponectin and thus affects blood flow distribution and metabolism within different sections of the same microcirculation. A 2008 study demonstrated that local production of adiponectin by microvascular endothelial cells might be involved in the regulation of cardiac function in the diabetic rat heart. 56 Similar results were also found in humans; adiponectin levels were found to correlate with microvascular coronary function and coronary blood flow in different regions of the myocardium. 57 The possibility exists, therefore, that inflamed microvascular networks are not only directly affected by, but also contribute to, the generalized loss of physiological adiponectin levels in metabolic disease states.
A few studies have attempted to correlate adiponectin plasma levels with microvascular complications in patients with diabetes. In 2008, Sharma et al. reported that in renal podocytes adiponectin acted via AMP kinase to ameliorate glomerular albumin permeability as well as suppress renal oxidative stress via reduced glomerular mass of renal NADPH oxidase 4. 58 An apparently paradoxical increase in total adiponectin levels has been observed in some patients with Type 1 diabetes who have microvascular complications, such as coronary artery disease. 59, 60 Other studies have reported increased urinary adiponectin excretion in diabetic patients with nephropathy characterized by microvascular damage. 61 Whether increases in adiponectin plasma levels in patients with diabetes are present throughout the entire course of the disease, or whether they are a transient compensatory mechanism meant to offset the loss of adiponectin that results from the hyperpermeable microcirculation that occurs in hyperglycemia remains unclear. Further research on the specific isoforms of adiponectin that circulate in the blood of patients with diabetes is necessary to fully evaluate the influence of changes in plasma and tissue levels of adiponectin in the pathophysiology of diabetes.
ADIPONECTIN AND THE MYOCARDIUM
In vitro studies have demonstrated that adiponectin promotes cell survival and inhibits cell death, which suggests that adiponectin may directly protect cardiomyocytes (in addition to its vascular actions that indirectly protect ischemic-reperfused cardiomyocytes). Indeed, studies have demonstrated that in addition to microvascular defects, Adipoq -/-mice have worse MIR injury-increased myocardial apoptosis and infarct size, and decreased cardiac function-compared with control mice. 16, 17 In heterozygous (Adipoq +/-) mice, in which circulating adiponectin concentrations are reduced by approximately half, MIR injury was increased compared to controls but the severity was less than that seen in Adipoq -/-animals. 17 This finding suggests that adiponectin levels not only correlate inversely with the risk of development of ischemic heart disease (as indicated by the human epidemiological data), but also are inversely related to the severity of a MIR insult. The worsening of MIR injury in Adipoq -/-mice was ameliorated by provision of full-length or globular adiponectin in a dose-dependent manner. 16, 17 These exciting results suggest that adiponectin might eventually be used as a novel therapeutic agent in the treatment of ischemic cardiac injury.
The antiapoptotic effect of full-length adiponectin in cultured, neonatal cardiomyocytes from Adipoq -/-mice is completely inhibited by transduction of a dominant-negative mutant of AMP kinase, 16 which suggests that adiponectin exerts its protective effects in cardiomyocytes largely via an AMP-kinase-mediated signaling pathway (Figure 3) . Indeed, Shinmura et al. have shown that the cardioprotective effects of short-term caloric restriction are mediated by adiponectin-stimulated activation of AMP kinase. 62 In adult rodent hearts subjected to MIR in vivo, however, a significant amount of adiponectin-mediated cardioprotection remains despite blockade of the AMP kinase signaling system; instead, full-length adiponectin upregulates cyclo-oxygenase 2 (COX-2) expression though activation of sphingosine kinase 1 and inhibits MIR-induced TNF overproduction in a COX-2-dependent fashion. 63 These seemingly controversial results underscore the complexity of adiponectin signaling and suggest that multiple signaling mechanisms are involved in cardioprotection by adiponectin in adult animals in vivo.
In low concentrations, NO release from eNOS or NO donors is known to be antiapoptotic and cardioprotective, 64 and as stated earlier, adiponectin is known to stimulate NO production via AMP-kinase-mediated eNOS phosphorylation. 43 Lack of adiponectin, therefore, might conceivably reduce NO production and thus render cardiomyocytes more susceptible to MIR ncpcardio_2007_280f3.eps 66 however, NO reacts with superoxide at a nearly diffusion-limited rate. The resultant reaction product, peroxynitrite, is extremely cytotoxic and causes oxidative as well as nitrative stress and tissue injury. 67 Of note, the genes that encode NADPH oxidase and iNOS belong to the same inflammatory gene family; therefore, given that adiponectin inhibits iNOS expression, adiponectin might also inhibit NADPH oxidase expression and subsequent superoxide production in ischemic-reperfused cardiomyocytes. Indeed, lack of adiponectin in Adipoq -/-mice results in enhanced expression of gp91 phox (the cytochrome b-245 heavy chain subunit of NADPH oxidase) and superoxide production in ischemic-reperfused hearts. 17 Treatment of these mice with globular adiponectin effectively inhibits both gp91 phox expression and superoxide production. 17 Owing to the double inhibitory effect of adiponectin on excess superoxide and NO production induced by ischemiareperfusion, peroxynitrite formation is intensified in Adipoq -/-mice after ischemia-reperfusion and is inhibited by exogenous adiponectin. 17 As peroxynitrite has been shown to be the most important nitrative species in causing severe nitrative stress and tissue injury, 68 adiponectin-mediated inhibition of excess peroxynitrite formation indicates that, in addition to its previously reported AMP kinase-mediated metabolic and COX-2-mediated TNF-suppressing actions, adiponectin might exert its anti-ischemic, cardioprotective effects via inhibition of peroxynitrite-induced oxidative and nitrative stress.
FUTURE DIRECTIONS
Numerous epidemiological studies have provided abundant evidence for a potential association between reduced adiponectin levels and cardiovascular disease. When coupled with work in animal models and cultured cells, these studies have elucidated multiple salutary effects of this fascinating, adipose-tissue-derived hormone. Indeed, animal models of adiponectin deficiency have shown that adiponectin has beneficial protective effects, including anti-inflammatory and angiogenic actions on the microvascular endothelium, and that provision of adiponectin can reduce MIR injury. Further work will reveal whether the various oligomeric forms of adiponectin have different effects in the vasculature and heart. Nevertheless, multiple research groups have convincingly demonstrated the beneficial pharmacologic properties of the globular domain of adiponectin, which would be easier to manufacture and administer to patients than its full-length version. Small fragments of adiponectin might also be biologically active, and chemical entities that can activate cell-surface adiponectin receptors should be sought and applied in human trials to test their potential benefit in various clinical settings.
CONCLUSIONS
Adiponectin is an abundant, oligomeric protein secreted from adipose tissue, which exhibits a variety of remarkable salutary responses that affect insulin resistance and vascular inflammation. The varied responses in multiple tissue types involve different signal transduction pathways; notably the AMP kinase and the PKA cascades in the endothelium, as well as AMP kinase and COX-2 signaling in cardiomyocytes. The resultant cellular effects of adiponectin include enhanced NO production, and inhibition of ROS and inflammatory NFκB signaling in the vasculature, as well as reduced MIR injury with suppression of TNF signaling, reduced cardiomyocyte apoptosis and suppression of oxidative and nitrative stress. The many potential benefits of adiponectin and its active derivative forms, such as the C-terminal globular domain, will probably find a place in the future management of endothelial dysfunction and myocardial protection. 
